Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 8;12:2. doi: 10.1186/s13045-018-0689-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 8 — a Adhesion assay of MM1.S exo on hTERT-MSCs: pre-treatment of hTERT-MSCs cells with MM1.S exo for 48 h increases MM1.S cell adhesion to mesenchymal cells. Treatment with exosomes pretreated with anti-AREG mAb reduces this effect. Right panel: a representative phase contrast micrograph showing the adhesion of MM1.S cells to exosome-treated hTERT-MSCs monolayer. b Evaluation by quantitative Real Time PCR of mRNA expression of OPG and RANKL in hTERT-MSC treated for 14 days with MM1.S exosomes in osteogenic differentiation medium (diff) (*p ≤ 0.05; **p ≤ 0.01). c IL8 mRNA expression was evaluated by real-time PCR in hTERT-MSCs treated for 24 or 48 h with MM1.S exosomes pretreated or not with anti-AREG mAb for 24 and 48 h. d IL8 protein release was evaluated by ELISA assay in the conditioned medium of hTERT-MSCs monolayer after 48 h treatment with MM1.S exosomes pretreated or not with anti-AREG mAb. *Exo vs untreated (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001); ^#Exo+AREG mAb vs Exo (^#p ≤ 0.05; ^##p ≤ 0.01). e Evaluation by quantitative real-time PCR of mRNA expression of CTSK and MMP9 in CD14⁺ monocytes untreated or treated for 6 days with rIL8, with the conditioned medium of BMMSC cells treated with MM1.S exosomes with or without SB225002 (*p ≤ 0.05; **p ≤ 0.01)